| Tumor necrosis factor α as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose ML Harrison, E Obermueller, NR Maisey, S Hoare, K Edmonds, NF Li, ... Journal of Clinical Oncology 25 (29), 4542-4549, 2007 | 310 | 2007 |
| Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative … F Fostira, M Tsitlaidou, C Papadimitriou, M Pertesi, E Timotheadou, ... Breast cancer research and treatment 134, 353-362, 2012 | 126 | 2012 |
| Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized … G Fountzilas, D Skarlos, U Dafni, H Gogas, E Briasoulis, D Pectasides, ... Annals of oncology 16 (11), 1762-1771, 2005 | 121 | 2005 |
| Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer: a Hellenic Cooperative Oncology Group phase II study G Fountzilas, D Tsavdaridis, A Kalogera-Fountzila, CH Christodoulou, ... Annals of oncology 12 (11), 1545-1551, 2001 | 105 | 2001 |
| Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial … A Bamias, U Dafni, A Karadimou, E Timotheadou, G Aravantinos, A Psyrri, ... Annals of oncology 24 (4), 1011-1017, 2013 | 103 | 2013 |
| XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with … D Pectasides, G Papaxoinis, KT Kalogeras, AG Eleftheraki, I Xanthakis, ... BMC cancer 12, 1-10, 2012 | 88 | 2012 |
| Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study A Psyrri, KT Kalogeras, R Kronenwett, RM Wirtz, A Batistatou, E Bournakis, ... Annals of oncology 23 (6), 1422-1427, 2012 | 86 | 2012 |
| Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study AK Koutras, KT Kalogeras, MA Dimopoulos, RM Wirtz, U Dafni, ... British journal of cancer 99 (11), 1775-1785, 2008 | 80 | 2008 |
| Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression E Razis, KT Kalogeras, V Kotoula, AG Eleftheraki, N Nikitas, R Kronenwett, ... Clinical Breast Cancer 12 (3), 183-193, 2012 | 74 | 2012 |
| Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials V Kotoula, K Chatzopoulos, S Lakis, Z Alexopoulou, E Timotheadou, ... Oncotarget 7 (4), 5074, 2016 | 72 | 2016 |
| HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy G Fountzilas, C Valavanis, V Kotoula, AG Eleftheraki, KT Kalogeras, ... Journal of translational medicine 10, 1-21, 2012 | 58 | 2012 |
| Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic … H Gogas, U Dafni, M Karina, C Papadimitriou, A Batistatou, M Bobos, ... Breast cancer research and treatment 132, 609-619, 2012 | 57 | 2012 |
| A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic … D Bafaloukos, H Linardou, G Aravantinos, C Papadimitriou, A Bamias, ... BMC medicine 8, 1-12, 2010 | 47 | 2010 |
| Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases AV Stavropoulou, F Fostira, M Pertesi, M Tsitlaidou, GE Voutsinas, ... PloS one 8 (3), e58182, 2013 | 46 | 2013 |
| Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with … G Fountzilas, U Dafni, M Bobos, V Kotoula, A Batistatou, I Xanthakis, ... BMC cancer 13, 1-16, 2013 | 45 | 2013 |
| TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting G Fountzilas, E Giannoulatou, Z Alexopoulou, F Zagouri, E Timotheadou, ... Oncotarget 7 (22), 32731, 2016 | 44 | 2016 |
| The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping S Lakis, V Kotoula, AG Eleftheraki, A Batistatou, M Bobos, T Koletsa, ... The Breast 23 (3), 234-243, 2014 | 44 | 2014 |
| Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients S Murray, E Timotheadou, H Linardou, AV Vrettou, I Kostopoulos, ... Lung Cancer 52 (2), 225-233, 2006 | 43 | 2006 |
| Significance of PIK3CA mutations in patients with early breast cancer treated with adjuvant chemotherapy: a Hellenic Cooperative Oncology Group (HeCOG) Study G Papaxoinis, V Kotoula, Z Alexopoulou, KT Kalogeras, F Zagouri, ... PloS one 10 (10), e0140293, 2015 | 39 | 2015 |
| Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model A Bamias, A Karadimou, S Lampaki, G Lainakis, L Malettou, ... BMC cancer 10, 1-12, 2010 | 36 | 2010 |
